Patent: 9,296,745
✉ Email this page to a colleague
Summary for Patent: 9,296,745
Title: | Diacylglycerol acyltransferase 2 inhibitors |
Abstract: | Derivatives of purine, 3H-imidazo[4,5-b]pyrimidine and 1H-imidazo[4,5-d]pyrazine of Formula I that inhibit the activity of the diacylglycerol acyltransferase 2 (DGAT2) and their uses in the treatment of diseases linked thereto in animals are described herein. |
Inventor(s): | Ahn; Kay (Lexington, MA), Boehm; Markus (Mansfield, MA), Cabral; Shawn (Groton, CT), Carpino; Philip A. (Newton, MA), Futatsugi; Kentaro (Quincy, MA), Hepworth; David (Concord, MA), Kung; Daniel W. (Salem, CT), Orr; Suvi (San Diego, CA), Wang; Jian (Belmont, MA) |
Assignee: | Pfizer Inc. (New York, NY) |
Application Number: | 14/384,508 |
Patent Claims: | see list of patent claims |
Details for Patent 9,296,745
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Glaxosmithkline Llc | TANZEUM | albiglutide | For Injection | 125431 | 04/15/2014 | ⤷ Try a Trial | 2032-04-06 |
Eli Lilly And Company | TRULICITY | dulaglutide | Injection | 125469 | 09/18/2014 | ⤷ Try a Trial | 2032-04-06 |
Eli Lilly And Company | TRULICITY | dulaglutide | Injection | 125469 | 09/04/2020 | ⤷ Try a Trial | 2032-04-06 |
Sanofi-aventis U.s. Llc | ADLYXIN | lixisenatide | Injection | 208471 | 07/27/2016 | ⤷ Try a Trial | 2032-04-06 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |